Lantern Pharma Inc. Stock-Based Compensation
Lantern Pharma Inc. (LTRN) reported Stock-Based Compensation of $548.17 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-14
- Lantern Pharma Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $198.94K, a 2.77% decline year-over-year.
- Lantern Pharma Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $143.69K, a 19.80% decline year-over-year.
- Lantern Pharma Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-06-30 was $160.63K, a 19.72% increase year-over-year.
- Lantern Pharma Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-03-31 was $147.75K, a 10.21% increase year-over-year.
- Lantern Pharma Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $651.00K, a 0.15% decline from fiscal 2024.
- Lantern Pharma Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $652.00K, a 35.89% decline from fiscal 2023.
- Lantern Pharma Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $1.02M, a 14.38% decline from fiscal 2022.
- Lantern Pharma Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $1.19M, a 23.52% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $548.17K 10-Q · filed 2026-08-14 | ||||
| 2025-12-31 | $198.94K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $342.62K derived: sum of 2 quarters · filed 2026-03-30 | $503.25K derived: sum of 3 quarters · filed 2026-03-30 | $651.00K 10-K · filed 2026-03-30 | |
| 2025-09-30 | $143.69K 10-Q · filed 2025-11-12 | $304.31K derived: sum of 2 quarters · filed 2025-11-12 | $452.06K 10-Q · filed 2025-11-12 | $656.67K derived: sum of 4 quarters · filed 2026-03-30 | |
| 2025-06-30 | $160.63K 10-Q · filed 2025-08-13 | $308.38K 10-Q · filed 2026-08-14 | $512.98K derived: sum of 3 quarters · filed 2026-03-30 | $692.15K derived: sum of 4 quarters · filed 2026-03-30 | |
| 2025-03-31 | $147.75K 10-Q · filed 2025-05-15 | $352.36K derived: sum of 2 quarters · filed 2026-03-30 | $531.52K derived: sum of 3 quarters · filed 2026-03-30 | $665.69K derived: sum of 4 quarters · filed 2026-03-30 | |
| 2024-12-31 | $204.61K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $383.77K derived: sum of 2 quarters · filed 2026-03-30 | $517.94K derived: sum of 3 quarters · filed 2026-03-30 | $652.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $179.17K 10-Q · filed 2025-11-12 | $313.34K derived: sum of 2 quarters · filed 2025-11-12 | $447.39K 10-Q · filed 2025-11-12 | $547.72K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $134.17K 10-Q · filed 2025-08-13 | $268.23K 10-Q · filed 2025-08-13 | $368.55K derived: sum of 3 quarters · filed 2025-08-13 | $559.31K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $134.06K 10-Q · filed 2025-05-15 | $234.38K derived: sum of 2 quarters · filed 2025-05-15 | $425.14K derived: sum of 3 quarters · filed 2025-05-15 | $817.53K derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $100.33K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $291.08K derived: sum of 2 quarters · filed 2025-03-27 | $683.47K derived: sum of 3 quarters · filed 2025-03-27 | $1.02M 10-K · filed 2025-03-27 | $1.07M 10-K · filed 2024-03-18 |
| 2023-09-30 | $190.75K 10-Q · filed 2024-11-07 | $583.14K derived: sum of 2 quarters · filed 2024-11-07 | $916.67K 10-Q · filed 2024-11-07 | $1.25M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $392.39K 10-Q · filed 2024-08-08 | $725.92K 10-Q · filed 2024-08-08 | $1.06M derived: sum of 3 quarters · filed 2024-08-08 | $1.36M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $333.53K 10-Q · filed 2024-05-09 | $663.63K derived: sum of 2 quarters · filed 2024-05-09 | $964.74K derived: sum of 3 quarters · filed 2024-05-09 | $1.25M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $330.10K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | $631.21K derived: sum of 2 quarters · filed 2024-03-18 | $920.74K derived: sum of 3 quarters · filed 2024-03-18 | $1.19M 10-K · filed 2024-03-18 | |
| 2022-09-30 | $301.11K 10-Q · filed 2023-11-08 | $590.65K derived: sum of 2 quarters · filed 2023-11-08 | $857.65K 10-Q · filed 2023-11-08 | $1.10M derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | $289.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $556.54K 10-Q · filed 2023-08-09 | $802.47K derived: sum of 3 quarters · filed 2023-08-09 | $1.03M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $267.00K 10-Q · filed 2023-05-09 | $512.93K derived: sum of 2 quarters · filed 2023-05-09 | $737.35K derived: sum of 3 quarters · filed 2023-05-09 | $983.03K derived: sum of 4 quarters · filed 2023-05-09 | |
| 2021-12-31 | $245.93K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $470.34K derived: sum of 2 quarters · filed 2023-03-20 | $716.03K derived: sum of 3 quarters · filed 2023-03-20 | $961.54K 10-K · filed 2023-03-20 | |
| 2021-09-30 | $224.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $470.10K derived: sum of 2 quarters · filed 2022-11-07 | $715.62K 10-Q · filed 2022-11-07 | ||
| 2021-06-30 | $245.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $491.20K 10-Q · filed 2022-08-08 | |||
| 2021-03-31 | $245.52K 10-Q · filed 2022-05-03 | ||||
| 2020-09-30 | $43.00K 10-Q · filed 2020-10-29 | $148.00K derived: sum of 2 quarters · filed 2020-10-29 | $167.00K 10-Q · filed 2020-10-29 | ||
| 2020-06-30 | $105.00K 10-Q · filed 2020-07-30 | $124.00K 10-Q · filed 2020-07-30 | |||
| 2019-09-30 | $32.00K 10-Q · filed 2020-10-29 | $38.00K derived: sum of 2 quarters · filed 2020-10-29 | $54.00K 10-Q · filed 2020-10-29 | ||
| 2019-06-30 | $6.00K 10-Q · filed 2020-07-30 | $22.00K 10-Q · filed 2020-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |